Mink Therapeutics, INC Form 4 insider transactions

MiNK Therapeutics director Peter Behner was granted 1,173 restricted stock units as compensation, increasing his beneficial ownership to 18,649 shares.

MiNK Therapeutics, Inc. Director Brian Corvese was granted 2,494 restricted stock units (RSUs) valued at $7.17 per unit, increasing his beneficial ownership to 47,151 shares.

MiNK Therapeutics, Inc. Director Robert Peter Kadlec was granted 1,883 restricted stock units as part of his board and committee compensation, increasing his direct beneficial ownership to 4,647 shares.

MiNK Therapeutics Director Peter Behner has increased his beneficial ownership in the company by acquiring 2,267 shares of common stock through a restricted stock unit grant, received in lieu of cash compensation.

MiNK Therapeutics Director Ulf Wiinberg has acquired 1,953 shares of common stock through a restricted stock unit grant, received in lieu of cash compensation for board and committee services.

MiNK Therapeutics Director Barbara Ryan acquired 2,476 shares of common stock through a restricted stock unit grant on June 2, 2025, as part of her board compensation.

Director Robert Peter Kadlec of MiNK Therapeutics, Inc. [INKT] reports acquiring and disposing of common stock and receiving restricted stock units (RSUs) in lieu of cash retainers.

Director Barbara Ryan acquired common stock and restricted stock units in MiNK Therapeutics, Inc.

Director Brian Corvese acquired 2,033 shares of MiNK Therapeutics through restricted stock units (RSUs) in lieu of cash retainers.

Director Peter Behner acquired common stock and restricted stock units (RSUs) of MiNK Therapeutics, Inc.

Director Ulf Wiinberg reports acquiring 1,593 shares of Mink Therapeutics common stock and disposing of 16,007 shares.

Robert Peter Kadlec, a director at MiNK Therapeutics, acquired stock options and restricted stock units, according to a recent SEC filing.

Director Barbara Ryan of MiNK Therapeutics acquired 24,229 shares of common stock through restricted stock units (RSUs) in lieu of cash retainers.

Brian Corvese, a director at MiNK Therapeutics, acquired 24,400 shares of common stock through restricted stock units (RSUs) as part of his board compensation.

Director Peter Behner of MiNK Therapeutics acquired 20,987 shares of common stock through restricted stock units (RSUs) in lieu of cash retainers.

A director of MiNK Therapeutics, Ulf Wiinberg, acquired 20,476 shares of common stock through restricted stock units and also indirectly disposed of 278,300 shares held in a family trust.

Director Barbara Ryan acquired common stock and restricted stock units in MiNK Therapeutics, Inc.

Director Peter Behner acquired 18,753 shares of MiNK Therapeutics common stock at $0.82 per share in lieu of cash retainers for board and committee compensation.

Director Ulf Wiinberg acquired 18,295 shares of Mink Therapeutics common stock at $0.82 per share and holds indirect ownership of 278,300 shares through a family trust.

Director Brian Corvese reports acquisition of Mink Therapeutics shares and restricted stock units (RSUs) in lieu of cash retainers.

Director Peter Behner acquired shares and restricted stock units in MiNK Therapeutics, Inc. on June 3, 2024.

Director Barbara Ryan acquired shares and restricted stock units (RSUs) of MiNK Therapeutics, Inc. on June 3, 2024.

Director Ulf Wiinberg reports acquisition of 15,077 shares and disposal of 105,410 shares of Mink Therapeutics common stock on June 3, 2024.

Director Brian Corvese of MiNK Therapeutics acquires shares through restricted stock units (RSUs) in lieu of cash retainers.

Director Peter Behner acquired shares and restricted stock units (RSUs) of MiNK Therapeutics, Inc. on March 1, 2024.

Director Barbara Ryan reported acquiring 18,685 shares of MiNK Therapeutics common stock at $0.95 per share and disposing of 86,617 shares on March 1, 2024.

Director Ulf Wiinberg reports acquisition of Mink Therapeutics shares and holding of restricted stock units (RSUs) in a recent SEC filing.

Director Brian Corvese acquired 18,816 shares of Mink Therapeutics common stock at $0.95 per share in lieu of cash retainers for board and committee compensation.